Clinical trials: COVID-19 Booster
COVID-19 Vaccine
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
The purpose of this study is to assess the safety, tolerability, and immunogenicity of booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT05197153
- Testing
- Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222
- Where
- 4 sites in Taiwan
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19 Pandemic
Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world.
- Trial name
- NCT05366296
- Testing
- A Lyophilized COVID-19 mRNA Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wuhan Recogen Biotechnology Co., Ltd.
Old Age; Debility, Vaccine Hesitancy
COVID-19 Vaccination Willingness in Older Adults Based on Self-determination Theory
Introduction: The COVID-19 vaccine is an effective measure for preventing and controlling COVID-19 epidemics, and the World Health Organization lists older adults as a high-priority group for COVID-19 vaccination.
- Conditions
- Old Age; Debility, Vaccine Hesitancy, Vaccine Refusal
- Trial name
- CVWIOABOSDT (NCT06575114)
- Testing
- Self-determination theory-based health education measures
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Jing-Shan Deng
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104333
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Type 1 Diabetes, Diabetes Mellitus, Type 1
Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes
Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory…
- Trial name
- NCT05233592
- Testing
- CGM
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Johns Hopkins University
COVID-19
Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.
This clinical trial is a single-blind, randomised study to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccine (Pfizer-BioNTech) as booster dose in adults, who…
- Trial name
- NCT05265065
- Testing
- Tozinameran - Standard Dose, Tozinameran - Fractional Dose
- Where
- Mongolia
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Double Vaccinated for COVID-19 (For Phase 1 of the Study), Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)
Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.
VIDO has developed a vaccine called COVAC-2. The COVAC-2 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1.
- Trial name
- NCT05226702
- Testing
- COVAC-2
- Where
- 3 sites in Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
- Trial name
- NCT05911048
- Testing
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
COVID Booster in Pregnancy and Lactation
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
- Trial name
- NCT05543993
- Testing
- Bivalent COVID-19 Booster
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
COVID-19
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older…
- Trial name
- NCT05770180
- Testing
- Recombinant COVID-19 variant vaccine (Sf9 cell), Recombinant COVID-19 vaccine (CHO cell), Recombinant COVID-19 vaccine (Sf9 cell)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination
Data from some studies indicate the decline in the effectiveness of the authorized COVID-19 vaccines due to antibody waning following vaccination and the emergence of different variants.
- Trial name
- NCT05545683
- Testing
- VLA 2001
- Where
- Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centro de Estudios en Infectogía Pediatrica
COVID-19
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
This is a Phase III, randomized, placebo-controlled, observer-blinded, parallel-group, multi-center study to assess the safety, reactogenicity, and immunogenicity of heterologous booster vaccination of SK SARS-CoV-2 recombinant…
- Trial name
- NCT05501522
- Testing
- GBP510 adjuvanted with AS03
- Where
- 4 sites in Colombia, Nepal
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Covid19
To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2
To evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 doses of BNT162b2
- Trial name
- NCT05200741
- Testing
- DelNS1-2019-nCoV-RBD-OPT1
- Where
- Hong Kong
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
COVID-19 Vaccines
Effect of a Third COVID-19 Booster Among Health Care Workers
A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022.
- Trial name
- NCT05373459
- Testing
- Third COVID-19 booster
- Where
- Hong Kong
- Volunteers
- 3,167 people, healthy volunteers welcome
- Sponsor
- Hong Kong Sanatorium & Hospital
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Adenovirus Type-5 Vectored COVID-19 Vaccine
The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China.
- Trial name
- NCT04568811
- Testing
- Adenovirus Type-5 Vectored COVID-19 Vaccine
- Where
- China
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Immunosuppression and COVID-19 Boosters
It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected.
- Trial name
- NCT05415267
- Testing
- diphtheria and tetanus toxoids (adsorbed) vaccine, COVID-19 vaccine
- Where
- 5 sites in Australia
- Volunteers
- 320 people
- Sponsor
- Kirby Institute